Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01208467 · ClinicalTrials.gov registry record
Prognostic Biomarkers in Patients With Endometrial Cancer
A clinical trial of Endometrial Adenocarcinoma and Recurrent Uterine Corpus Carcinoma, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- 2,824
- Enrollment target
- 1
- Study location
NCT01208467 is a study of Endometrial Adenocarcinoma and Recurrent Uterine Corpus Carcinoma that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 2,824 participants, above the 123-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (2196% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01208467, a study of Endometrial Adenocarcinoma and Recurrent Uterine Corpus Carcinoma, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- 2,824 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying prognostic biomarkers in tissue samples from patients with endometrial cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,824 participants |
| Start Date | 2010-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01208467
The ClinicalTrials.gov registry entry for NCT01208467 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,824 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 123-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (2196% higher). The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Endometrial Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Laboratory Biomarker Analysis is the first listed.
NCT01208467 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01208467 about?
NCT01208467 is a clinical study titled "Prognostic Biomarkers in Patients With Endometrial Cancer". This research study is studying prognostic biomarkers in tissue samples from patients with endometrial cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
What is the current status of trial NCT01208467?
This trial is currently completed. The enrollment target is 2,824 participants. The study started on 2010-09.
What conditions does trial NCT01208467 study?
This clinical trial studies the following conditions: Endometrial Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer.
What interventions are being tested in trial NCT01208467?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT01208467?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01208467 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RECRUITING · Phase 2
-
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RECRUITING · Phase 2
-
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
RECRUITING · Phase 1
-
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
ACTIVE NOT RECRUITING · Phase 2
-
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Endometrial Adenocarcinoma
All registered trials for this condition
Recurrent Uterine Corpus Carcinoma
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.